Berberine-doped liposomes enhance Factor IX mutant mRNA delivery for protein replacement therapy in Hemophilia B

Q: What type of study is this?

This is a Experimental Study study.

Porkizhi Arjunan; Gokulnath Mahalingam; Harini Manogaran; Mohankumar Murugesan; Saravanabhavan Thangavel; Srujan Marepally

doi:10.1039/d5pm00135h

January 1, 2025RSC PharmaceuticsOpen Access

Berberine-doped liposomes enhance Factor IX mutant mRNA delivery for protein replacement therapy in Hemophilia B

View Full Paper

Ask AI

Bookmark

Share

Key Points

Enhanced mRNA delivery was successfully achieved using berberine-doped liposomes for hemophilia B treatment.
The study demonstrates significant improvement in hepatic delivery efficiency of factor IX mRNA, crucial for therapy.
Utilizing a novel method, the mRNA delivery system showcased effectiveness in addressing FIX deficiency.
Findings suggest berberine-doped liposomes could revolutionize gene therapy efforts for hemophilia B patients.

Implication

Experimental approach improves mRNA delivery efficiency in hemophilia B, indicating potential for novel therapy.

Abstract

Hemophilia B, caused by Factor IX (FIX) deficiency, remains the best candidate for mRNA-based gene therapy. However, efficient hepatic delivery of mRNA continues to be a significant challenge. In this...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Arjunan et al. (2025) studied this question.

synapsesocial.com/papers/68f0d5eb105731330a2b21bb https://doi.org/10.1039/d5pm00135h

View Full Paper

Ask AI

Bookmark

Share

Berberine-doped liposomes enhance Factor IX mutant mRNA delivery for protein replacement therapy in Hemophilia B

Key Points

Implication

Abstract

Discussion

Cite This Study

Berberine-doped liposomes enhance Factor IX mutant mRNA delivery for protein replacement therapy in Hemophilia B

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading